Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review
- 9 March 2011
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 25 (s2) , 28-33
Abstract
Background There is limited evidence regarding the efficacy and safety of retinoids in different psoriasis subtypes.Objective To systematically review the available literature on: (i) modalities of administration and prescription of oral retinoids as single agent or combined therapy for the treatment of plaque‐type psoriasis (PV), nail psoriasis and localized and generalized pustular psoriasis : initial and optimal dosage; (ii) skeletal toxicity of retinoid for the treatment of psoriasis.Methods A systematic literature search was carried out in MEDLINE, EMBASE, and Cochrane Library databases from 1975 to 2010 searching for randomized controlled trials and observational studies evaluating 1) various dosages of retinoid in psoriasis and 2) skeletal toxicity of retinoid in psoriasis. Articles were limited to human subjects and English/French languages.Results Efficacy of retinoids in psoriasis. Among 1348 identified references, 44 published studies were included. Starting daily dosages between 10 and 25 mg and stepwise escalation were associated with higher clinical efficacy and lower incidence of adverse events in comparison with higher doses and regimens rapidly reaching optimal dose. Retinoids as single agent therapy appeared to show limited efficacy in PV, while the good clinical efficacy reported in pustular forms should be cautiously considered, given the spontaneously remitting course of the disease. Combining retinoids with phototherapy appeared to be highly effective in patients with PV.Potential skeletal toxicity of retinoids. 15 published studies out of 105 identified references were included. There is no strong evidence of an increased risk of skeletal abnormalities in psoriasis patients treated with retinoids.Conclusion Acitretin appears to provide better efficacy in pustular psoriasis than in PV as a single agent treatment. There is no evidence for skeletal toxicity of retinoids in the setting of psoriasis, and accordingly monitoring this risk through X‐ray is not warranted.Keywords
This publication has 64 references indexed in Scilit:
- The safety of etretinate as long-term therapy for psoriasis: Results of the Etretinate Follow-up StudyJournal of the American Academy of Dermatology, 1995
- Low-dose short-term cyclosporine versus etretinate in psoriasis: Improvement of skin, nail, and joint involvementJournal of the American Academy of Dermatology, 1995
- Photochemotherapy for severe psoriasis without or in combination with acitretin: A randomized, double-blind comparison studyJournal of the American Academy of Dermatology, 1991
- A 12-month treatment of severe psoriasis with acitretin: Results of a Canadian open multicenter studyJournal of the American Academy of Dermatology, 1991
- Acitretin plus UVB therapy for psoriasisJournal of the American Academy of Dermatology, 1991
- A retrospective study of bone changes in adults treated with etretinateJournal of the American Academy of Dermatology, 1989
- Acitretin versus etretinate in psoriasisJournal of the American Academy of Dermatology, 1988
- Effects of retinoids in boneJournal of the American Academy of Dermatology, 1988
- Acitretin improves psoriasis in a dose-dependent fashionJournal of the American Academy of Dermatology, 1988
- Extraspinal Tendon and Ligament Calcification Associated with Long-Term Therapy with EtretinateNew England Journal of Medicine, 1986